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A greater incidence of tobacco consumption occurs among individuals with psychiatric con-
ditions including post-traumatic stress disorder (PTSD), bipolar disorder, major depression,
and schizophrenia, compared with the general population. Even when still controversial,
it has been postulated that smoking is a form of self-medication that reduces psychiatric
symptoms among individuals with these disorders.To better understand the component(s)
of tobacco-inducing smoking behavior, greater attention has been directed toward nicotine.
However, in recent years, new evidence has shown that cotinine, the main metabolite
of nicotine, exhibits beneficial effects over psychiatric symptoms and may therefore pro-
mote smoking within this population. Some of the behavioral effects of cotinine compared
to nicotine are discussed here. Cotinine, which accumulates in the body as a result of
tobacco exposure, crosses the blood-brain barrier and has different pharmacological prop-
erties compared with nicotine. Cotinine has a longer plasma half-life than nicotine and
showed no addictive or cardiovascular effects in humans. In addition, at the preclinical
level, cotinine facilitated the extinction of fear memory and anxiety after fear conditioning,
improved working memory in a mouse model of Alzheimer’s disease (AD) and in a monkey
model of schizophrenia. Altogether, the new evidence suggests that the pharmacological
and behavioral effects of cotinine may play a key role in promoting tobacco smoking in indi-
viduals that suffer from psychiatric conditions and represents a new potential therapeutic
agent against psychiatric conditions such as AD and PTSD.
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INTRODUCTION
The use of tobacco dates back as early as 5,000–3,000 BC, when
tobacco plants were first cultivated in South America (Gately,
2003). Initially, tobacco was regarded has a medicinal plant to
be used for medical purposes such as, a painkiller for earaches and
toothaches (Balls, 1962). However, later studies clearly established
the deleterious effects of tobacco smoking on health (Peto et al.,
1996). As a result, the progressive establishment of more restrictive
anti-tobacco laws has discouraged tobacco smoking worldwide.
These new restrictions and public health campaigns have dra-
matically decreased tobacco use. However, there is a high rate of
tobacco consumption among individuals that suffer from mental
disorders such as, major depression disorder (MDD), schizophre-
nia, and post-traumatic stress disorder (PTSD; Leonard et al., 2001;
Weaver and Etzel, 2003; Thorndike et al., 2006; Buggia-Prevot et al.,
2008; Aubin et al., 2012). The idea that tobacco consumption
in these populations is a form of self-medication is controver-
sial and some evidence suggests that smoking is associated with
poorer mental health outcomes in some mental disorders such
as, bipolar and schizoaffective disorder (Dodd et al., 2010). The
desire to identify the component of tobacco that may explain
this correlation has encouraged the study of the mental effect(s)
of nicotine [3-(1-methyl-2-pyrrolidinyl) pyridine], an alkaloid
that is present in tobacco leaves, over the psychiatric symptoms.
Nicotine treatment had been shown to improve cognitive func-
tion including attention, concentration, executive function, and
learning and memory (Elzinga and Bremner, 2002; Horner and
Hamner, 2002; Bowie and Harvey, 2005; Gray and Roth, 2007;
Tapia et al., 2007; Burriss et al., 2008; Luck and Gold, 2008; Terry
et al., 2008; Hinkelmann et al., 2009; Johnsen and Asbjornsen,
2009; Veltmeyer et al., 2009; Baune et al., 2010). However, nico-
tine’s undesirable cardiovascular and addictive side-effects have
limited its therapeutic use (Karaconji, 2005). Recently, new stud-
ies have shown that the main metabolite of nicotine, an alkaloid
named cotinine [(5S)-1-methyl-5-(3-pyridyl)-pyrrolidin-2-one],
has beneficial therapeutic properties, while not having nicotine’s
negative side-effects. In preclinical studies, cotinine has shown
to improve reference and working memories, attention, and the
extinction of fear memory, as well as to reduce both the star-
tle response and anxiety in animal models of aging, Alzheimer’s
disease (AD), PTSD, and schizophrenia (Figure 1). Here the psy-




Cotinine is an alkaloid found in tobacco leaves and the main
metabolite of nicotine. The active form of cotinine, the isomer
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FIGURE 1 | A schematic comparison of the behavioral effects of nicotine and cotinine.
S(-)-cotinine accumulates in the body after tobacco consumption.
The pharmacokinetic profiles of cotinine administered orally or
intravenously have been investigated in humans. These reports
show that cotinine is well-absorbed orally (De Schepper et al.,
1987), has a long plasma half-life (19–24 h; Benowitz et al.,
1983; Benowitz and Sharp, 1989) and crosses the blood-brain
barrier (Riah et al., 1998). Approximately 80–85% of nico-
tine is metabolized in the liver and converted into cotinine by
enzymes such as cytochrome P450 2A6 (CYP2A6; Lewis et al.,
1999) and cytochrome P4502A5 (CYP2A5) in human and mouse,
respectively (Donato et al., 2000; Visoni et al., 2008).
In humans, cotinine is excreted in the urine, mainly as trans-
3′-hydroxycotinine (90% of cotinine) and glucuronide (Caldwell
et al., 1992; Ghosheh and Hawes, 2002; Kuehl and Murphy,
2003).
The expression of different variants of the CYP2A6 gene, cod-
ing for enzymes with different catalytic activities, influences the
level of cotinine achieved in the body after nicotine consump-
tion and, seems to influence nicotine addiction (Malaiyandi et al.,
2006; Strasser et al., 2007). For example, individuals that express
a catalytically deficient form of CYP2A6 (i.e., CYP2A6∗4) showed
a lower rate of cigarette consumption compared with individuals
that express the normal allele (Yamanaka et al., 2004). The alleles
that express the polymorphic forms of the CYP2A6 gene, with low
or high enzymatic activity, are distinctly represented in diverse eth-
nic groups (Bramer and Kallungal, 2003; Nakajima et al., 2006).
The distinct expression of the different forms of CYP2A6 may
explain the varying metabolism of cotinine observed in individuals
of diverse ethnic backgrounds (Nakajima et al., 2006). Therefore
cotinine metabolism and, consequently, smoking behavior can be
influenced by ethnicity. Furthermore, other factors such as the
consumption of a specific food can also affect cotinine metabo-
lism (Nakajima et al., 2006). For example, some components of
grapefruit juice inhibit the activity of CYP2A6 and, consequently,
cotinine synthesis (Tassaneeyakul et al., 2000; Hukkanen et al.,
2006).
COTININE PHARMACODYNAMIC EFFECTS
Early studies of cotinine effects in humans showed that cotinine
has a good safety profile (Borzelleca et al., 1962; Bowman and
Mc, 1962). One of these seminal studies demonstrated that daily
doses of cotinine of up to 1,800 mg for a period of 4 days did
not induce deleterious side-effects in humans (Bowman and Mc,
1962). Another clinical study investigating the psychogenic effects
of cotinine showed that when administered intravenously to absti-
nent smokers, this compound reduced the self-reported irritability
and tobacco cravings experienced by the participants (Benowitz
et al., 1983). A follow-up phase II clinical study investigated the
effects of cotinine on smoking cessation in an inpatient, 10-day
study in abstinent cigarette smokers (Hatsukami et al., 1997). This
study showed that oral cotinine treatment of up to 160 mg/day
had no addictive, cardiovascular (e.g., heart rate and blood pres-
sure), or behavioral effects in individuals between 21 and 42 years
of age (Hatsukami et al., 1997). A follow-up study from the same
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research group also found that cotinine at the doses studied did
not help with tobacco cessation and antagonized the reduction of
the withdrawal symptoms induced by a nicotine patch (Hatsukami
et al., 1998). These results confirmed that orally administered coti-
nine exhibits behavioral effects in humans, likely by modulating
the nAChR sensitivity to agonists; however, this concept requires
further experimental validation.
Cotinine is a cognitive enhancer in a mouse model of Alzheimer’s
Disease
Cotinine has been shown to prevent working and reference mem-
ory loss in a mouse model of AD (Echeverria et al., 2011). In
this study, the ability of cotinine to prevent plaque development
and memory loss in the Tg6799 mice (Ohno et al., 2006) was
investigated. Two-month-old Tg and same age non-Tg (NT) mice
were orally treated with vehicle (PBS) or 2.5 mg/kg of cotinine
for 4.5 months via gavage and tested for working memory using
the circular platform, the Radial Arm Water maze (RAWM), and
cognitive interference tests. These behavioral study showed that
cotinine prevented memory loss in Tg6799 mice and significantly
decreased plaques burden in the cortex of the Tg6799 mice. Coti-
nine treatment also reduced the number and size of the amyloid
plaques. The decrease in plaque load also correlated with a decrease
in the levels of insoluble Aβ in the cortex of the cotinine-treated Tg
mice when compared with the vehicle-treated Tg mice (Echever-
ria et al., 2011). This evidence suggest that cotinine may be a new
therapeutic agent against this devastating condition (Echeverria
and Zeitlin, 2012).
Cotinine reduced anxiety and fear in a mouse model of PTSD – like
symptoms
Post-traumatic stress disorder is an anxiety disorder that appears
after exposure to life-threatening events (Martenyi et al., 2007).
PTSD is characterized by symptoms such as anxiety, fear, work-
ing memory impairment, hyperarousal, emotional numbing, and
sleep disorders. These symptoms have been associated with a per-
manent alteration of the physiological response to stress induced
by over-activation of the hypothalamus-pituitary-adrenal axis
(Yehuda et al., 1991). These changes are generally accompanied
by dysregulation of several neurotransmitter systems including
the serotoninergic, dopaminergic, noradrenergic, and cholinergic
systems. The hyperarousal and aggressive behavior observed in
patients with PTSD are caused, at least in part, by a decrease in
serotonin neurotransmission (Nutt, 2000). Consistent with this
idea, serotonin reuptake inhibitors (SSRIs) such as paroxetine and
sertraline are currently used in the treatment of PTSD (Brady et al.,
2000; Davidson et al., 2001; Brady and Clary, 2003; Corchs et al.,
2009; Stein et al., 2009). Because serotonin promotes acetylcholine
release, and acetylcholine signaling positively affects attention and
memory, an increase of serotonin levels in the brain, may simulta-
neously improve mood, reduce aggressiveness (Buhot et al., 2000),
and positively affect cognitive abilities. Although SSRIs are useful
in the treatment of PTSD (Cohen et al., 2000), they are effec-
tive only in a small percentage of patients (approximately 30%;
Veltmeyer et al., 2009).
Post-traumatic stress disorder patients are commonly heavy
smokers, and an association between tobacco dependence and
PTSD has previously been established (Hapke et al., 2005). In
the search of new drugs that could diminish fear and anxiety and
enhance the extinction of fear memories, rodent models of fear
conditioning (FC) has been extensively used. These animal mod-
els have permitted to characterize the effect of drugs, including
cotinine, over anxiety, fear, and contextual memory in anxiety dis-
orders. FC is a broadly used model of associative memory that
involves the pairing of neutral conditioning stimuli (CS; sound
and context) with an aversive unconditioned stimulus (US; elec-
tric shock). After conditioning, the presentation of the CS alone
elicits both a conditioned fear response (freezing behavior) and
anxiety in the animal. Experimentally, the extinction of contex-
tual fear (FE) after FC is expressed as a progressive decrease in fear
responses attained after repetitive exposures to the CS (context)
in the absence of the pairing with an aversive US (Steckler and
Risbrough, 2012).
A devastating symptom in PTSD is the failure to extin-
guish traumatic memories that force the patient to continue
re-experiencing the trauma (Izquierdo et al., 2004). Thus, the
identification of drugs that would enable the extinction of fear
memories would be an essential therapeutic goal.
One recent study investigated the effect of pre- and post-
treatment with cotinine over the stability of contextual fear mem-
ory after repetitive or single re-exposure to the CS (Zeitlin et al.,
2012). Male adult mice were pre-treated or post-treated with coti-
nine before or after FC, respectively, and tested for fear responses
and anxiety after being exposed to the CS (context). These stud-
ies showed that cotinine accelerated the extinction and reduced
the stability of the contextual fear memory. FE is considered a
“new learning” process that involves the acquisition of inhibitory
memories that compete with the original fear memory consolida-
tion. For this reason, it has been proposed that cognitive enhancers
may have a positive effect over the extinction of fear memories.
Thus the improvement of cognitive abilities induced by cotinine
may be relevant for its effects on FE. Thus, cotinine may pro-
mote the extinction of contextual fear memory by stimulating the
acquisition of new inhibitory memories.
In addition, because cotinine reduces anxiety and helps to
extinguish fear memory, it is feasible that cotinine may also be
useful, alone or in a combined treatment, with psychotherapy
to reduce both non-cognitive and cognitive symptoms of PTSD.
However, these ideas need to be tested in placebo-controlled
clinical trials.
Cell signaling changes associated with fear extinction triggered by
cotinine
This enhancement of contextual FE in mice subjected to FC
described above, correlated with an increase in the extracellular
signal-regulated kinases (ERK)1/2 (ERKs) activity in the hip-
pocampus (Chen et al., 2005; Fischer et al., 2007). This increase
has been regarded as a key molecular event during the fear extinc-
tion process because this brain region is involved in contextual FE
(Bouton et al., 2006; Quirk and Mueller, 2008) and also because
that ERK1/2 inhibition immediately after memory retrieval pre-
vented the extinction of contextual memory (Chen et al., 2005).
Consistent with these findings, the enhancement of FE induced
by cotinine treatment in the C57BL/6, mice positively correlated
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with an increase in the levels of the active form of ERK1/2
(phospho-ERKs) in the hippocampus.
In addition this study showed that cotinine also reduced anxiety
in the conditioned mice. Since it has been demonstrated that coti-
nine inhibited serotonin reuptake and increased its spontaneous
release in rat brains (Fuxe et al., 1979), an increase in serotonin in
the brain induced by cotinine may explain the reduction in anxi-
ety after FC in the cotinine-treated mice. A similar effect may also
explain the common perception of a “calming effect” experienced
by tobacco smokers.
COTININE, IS A MEMORY ENHANCER IN ANIMAL MODELS OF
SCHIZOPHRENIA-LIKE SYMPTOMS
Effect of smoking on psychiatric symptoms in schizophrenia
Schizophrenia is a mental disorder characterized by cognitive
deficits and both positive and negative symptoms (Van Snellen-
berg, 2009). The positive symptoms include delusions, hallucina-
tions, and difficulty in thought organization and oral expression.
The negative symptoms include deficits in attention and motiva-
tion, social withdrawal, and emotional numbness (Van Snellen-
berg, 2009). Although the causes of schizophrenia are not well
understood, abnormalities in the activity of several neurotrans-
mitters such as, dopamine, acetylcholine, gamma-aminobutyric
acid (GABA), and glutamate have been proposed (Lang et al.,
2007). Since the development of clozapine, current drugs used
to treat schizophrenia are mostly antagonists of the serotonin-
ergic/dopaminergic signaling systems. These drugs have been
effective in the management of positive psychotic symptoms; how-
ever, they do not effectively target the negative symptoms and
cognitive deficits observed in schizophrenic patients. Thus, the
identification of new drugs are needed to adequately treat these
symptoms (Biedermann and Fleischhacker, 2011; Karam et al.,
2012).
Patients with schizophrenia may often die prematurely due
to health risk factors commonly associated with this condition
including obesity and smoking behavior (Sagud et al., 2009; van
Os and Kapur, 2009; von Hausswolff-Juhlin et al., 2009; Kelly et al.,
2011).
A percentage of patients report, that smoking helps in decreas-
ing psychiatric symptoms (Glynn and Sussman, 1990) which,
become worse during tobacco withdrawal (Dalack and Meador-
Woodruff, 1996). There are few and incomplete clinical data
supporting the therapeutic effects of cotinine in psychiatric con-
ditions, however, in one clinical study it was found that smok-
ing high-nicotine cigarettes, compared to smoking de-nicotinized
cigarettes, reduced negative symptoms without affecting pos-
itive symptoms (Smith et al., 2002). This effect is consid-
ered to be the result of the increase of dopamine levels in
the nucleus accumbens and prefrontal cortex induced by nico-
tine (Corrigall and Coen, 1991). This increase in dopamine
may stimulate active coping, improve attention, environmen-
tal engagement, and emotional responding, that are com-
monly absent in schizophrenic patients with prominent negative
symptoms.
Cognitive impairment is one of the main challenges experi-
enced by these patients. Growing evidence suggests that a deficit
in cholinergic neurotransmission plays an important role in
mediating cognitive deficits (Araki et al., 2002; Levin, 2002; Money
et al., 2012). This evidence suggests that activation of the nicotinic
receptors can be useful in treating some symptoms of schizophre-
nia particularly the cognitive deficits (Taly et al., 2009; Toyohara
and Hashimoto, 2010).
The nicotinic receptors as targets of cotinine effects in
schizophrenia
The nicotinic receptors are involved in mediating attention, sen-
sory gating, and learning and memory (AhnAllen, 2012; Yakel,
2012). The most broadly expressed nicotinic receptor (90%) is
formed by α4 and β2 subunits and binds nicotine with high affin-
ity while, not binding α-bungarotoxin (McGehee and Role, 1995);
this receptor is highly represented in the striatum and substantia
nigra and, poorly expressed in the neocortex and hippocampus
(Rubboli et al., 1994b).
No less relevant, although less expressed, is the α7 nicotinic
acetylcholine receptor (α7 nAChR), a low affinity receptor for
nicotine that is highly expressed in the midbrain, neocortex, thal-
amus, and hippocampus, with lower levels in the striatum (Sugaya
et al., 1990; Freedman et al., 1993; Rubboli et al., 1994a,b). This
receptor that has high affinity for α-bungarotoxin (McGehee and
Role, 1995) and, plays a key role mediating several cognitive
functions including attention, memory, executive function, and
sensory gating (Woodruff-Pak and Gould, 2002; Leiser et al., 2009;
AhnAllen, 2012).
A cholinergic deficit has been proposed as a factor leading to
cognitive impairment in schizophrenia. Numerous studies have
shown that expression of the α7 nAChR is decreased in the brains
of patients with schizophrenia when compared to healthy controls
(Breese et al., 2000; Leonard et al., 2000). This idea is supported by
clinical evidence showing that the acetylcholinesterase inhibitor,
galantamine, which increases the synaptic levels of acetylcholine,
improved the cognitive abilities in patients with schizophrenia
(Ago, 2010; Ago et al., 2011).
The high rate of smoking in individuals with schizophrenia,
although not a evidence of causation, has permitted speculation
of the beneficial effect of a tobacco-derivative, but not smoking
itself (Dalack and Meador-Woodruff, 1999) on some schizophre-
nia symptoms such as working memory impairment (Leonard
et al., 1998, 2001). For example, evidence has been reported sug-
gesting that α7 nAChR expression is significantly lower in schizo-
phrenic non-smokers than in control non-smokers (Mexal et al.,
2010).
In a rat model of Schizophrenia-like symptoms, the administra-
tion of nicotine attenuated the working memory deficits induced
by the dopamine antagonist dizocilpine (Levin et al., 1998; Ciamei
et al., 2001). In patients with schizophrenia, nicotine administra-
tion via a nasal spray has shown to ameliorate deficits in working
memory, attention, and anxiety (Smith et al., 2006; Buckley et al.,
2007). In addition, other clinical studies have shown that chronic
treatment with nicotine improved the cognitive abilities in schizo-
phrenic patients treated with antipsychotics (McEvoy et al., 1999;
Freedman et al., 2008).
Several modulators of nAChRs have been tested against schizo-
phrenia. For example, a partial agonist of the α7 nAChR, DMXB-A
(GTS-21) was investigated in a phase 2 clinical study investigating
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the therapeutic effects of this drug over the symptoms of schizo-
phrenia. Although GTS-21 improved some negative symptoms, it
did not ameliorate the cognitive deficits observed in schizophrenic
patients (Olincy and Stevens, 2007; Freedman et al., 2008).
Despite cotinine acting as a weak agonist (100 times less potent
than nicotine) of the nAChRs, in rats it reversed the cognitive
deficits induced by antagonism of the glutamate receptor, N -
methyl-d-aspartate receptor (NMDAR), with ketamine. In this
rodent model cotinine improved sustained attention and atten-
uated behavioral alterations induced by ketamine (Terry et al.,
2012).
This pro-cognitive effect is not limited to rodent models of
this disorder as cotinine, at similar doses, also improved per-
formance accuracy on the delayed matching to sample (DMTS)
task in aged rhesus monkeys. The DMTS task assesses recogni-
tion memory for novel non-verbal patterns, and tests short-term
visual memory. This test has 19 outcome measures, including
latency to response, the number of correct choices selected, and
the probability of an error after a correct or incorrect response. In
this task, cotinine-treated monkeys performed significantly better
than vehicle-treated controls (Terry et al., 2005), indicating that
cotinine improved visual short-term memory. These results also
suggest that cotinine is a general cognitive enhancer that is useful
in different species and types of cognitive abilities.
But the positive effects of cotinine are not limited to cognitive
abilities. A recent study tested the effect of acute subcutaneous
(0.03–10 mg/kg) and chronic oral administration of cotinine on
sustained attention and behavioral alterations in rats induced by
the glutamate (NMDA) antagonist MK-801 (Terry et al., 2012).
The effects of cotinine were assessed in a five-choice serial reac-
tion timed task (5CSRTT), a test broadly used to measure visual
attention and impulsivity in rats. The 5CSRTT is implemented
in a specially designed operant chamber with multiple response
locations (“nine-hole box”) using food reinforcers to maintain
performance on baseline sessions (about 100 trials). The test gives
the rat a brief 0.5 s visual stimulus, measuring the time, and accu-
racy of the animal’s reactions, as well as the errors made by
the rat. The 5CSRTT is used for measuring various aspects of
attentional control over performance with its main measures of
accuracy, premature responding, correct response latencies, and
latency to collect earned food pellets (Robbins, 2002; Robinson
et al., 2009).
The results showed that acute treatment with cotinine dimin-
ished MK-801-induced impairments in accuracy and elevations
in timeout responses while increasing the number of completed
trials. Furthermore, chronic treatment with cotinine induced sim-
ilar beneficial effects even when the difficulties of the task were
increased. The authors concluded that cotinine was useful in
improving sustained attention and, in decreasing the impulsive
and compulsive behaviors that were related to the postulated gluta-
mate receptor signaling dysfunction in schizophrenia (Terry et al.,
2012).
Effect of cotinine on sensory gating in animal models of
schizophrenia
A deficit in sensory gating is also a characteristic of schizophrenic
patients as well as patients with other psychiatric conditions such
as PTSD, borderline personality disorder, and bipolar disorder
(Braff et al., 1992; Swerdlow et al., 2006). Individuals with this
deficit cannot filter out irrelevant stimuli, as their brains are unable
to inhibit its responsiveness to similar and repeated stimuli. The
activation of cholinergic nicotinic receptors in the hippocam-
pus is one of the main molecular mechanisms that control this
inhibitory gating. Because the α7 nAChR is required for support-
ing sensory gating abilities (Freedman et al., 1994), a cognitive
ability that is reduced in the patients with schizophrenia, this
receptor is considered a potential therapeutic target for dimin-
ishing sensory gating deficit in this disorder (Olincy and Stevens,
2007).
The NMDAR antagonist, dizocilpine, or the dopamine ago-
nist, apomorphine are used in rodents to induce memory and
sensory gating deficits resembling those observed in persons with
schizophrenia (Seillier and Giuffrida,2009). For example,apomor-
phine is used to induce in rodents the deficit in prepulse inhibition
(PPI) observed in schizophrenia. PPI is the decrease in the star-
tle response to an auditory stimulus after repetitive exposure to
the stimulus and a measure of sensory gating. The sensory gating
deficit is expressed as an increase in the startle response (Geyer,
2006). To assess the effect of drugs on PPI animals are treated
with vehicle, or the study drug, and are exposed to a weak acoustic
stimulus (the prepulse); then, changes in the reflexive flinching
response (startle) displayed as a result of a second stimulus of
higher intensity (the pulse) is measured. Effective antipsychotic
agents prevent the inhibition of PPI induced by psychogenic com-
pounds such as apomorphine and dizolcipine. Previous studies
have shown that nicotine blocks the apomorphine-induced dis-
ruption of the PPI of the acoustic startle in rats (Suemaru et al.,
2004).
In fact, several studies have reported a positive effect of smoking
on sensory gating and cognitive function in schizophrenia. In one
study, the relationship between sensory gating and smoking lev-
els was assessed by investigating the correlation between PPI and
smoking behavior in schizophrenic and control patients (Rabin
et al., 2009). The authors found that schizophrenic non-smokers
have poorer PPI performances than schizophrenic smokers, whose
levels did not differ from non-schizophrenic controls.
In addition to the observed effects of nicotine on sensory gat-
ing, other studies have demonstrated that nicotine also improved
other schizophrenic symptoms (Lyon, 1999). These results support
the view that smoking is a form of self-medication to alleviate
psychotic symptoms and the unpleasant side-effects of antipsy-
chotics (Matthews et al., 2011). Interestingly, cotinine, the long-
lived metabolite of nicotine, also ameliorated the apomorphine-
induced deficits in PPI of the acoustic startle response in rats
(Risner et al., 1985; Terry et al., 2005). This result suggested that
cotinine may have antipsychotic effects and underlie the ben-
eficial effects of nicotine on attention and sensory gating, in
addition to its predicted positive effect over working memory.
In addition, as mentioned before, cotinine facilitates fear extinc-
tion a measure of executive function which has been found also
impaired in people suffering from schizophrenia (Holt et al.,
2009). Unfortunately, no clinical studies have been performed
to investigate the effect of cotinine over these symptoms in
schizophrenia.
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Table 1 | Potencies and affinities of cotinine and nicotine to different subtypes of nAChRs in the rat brain and values of acute toxicity in mice.
*I/IC50 [3H] nicotine I/IC50 125I-labeled α-bungarotoxin Male Female
LD50 LD90 LD50 LD90
Nicotine 100/(2±0.1)×10−7 100/(1±0.3)×10−5 31±4 43±6 37±6 51±9
Cotinine 100/(2±0.2)×10−3 100/(1±0.2)×10−3 2±0.1 4±0.1 3±0.1 4±0.1
*I/IC50, percentage maximum inhibition/concentration of drug that inhibits 50% radioligand binding (in M). Values of IC50, mean±SD. LD, lethal dose with nicotine
attributed 100% toxicity (Riah et al., 1999).
MOLECULAR MECHANISMS POTENTIALLY MEDIATING THE
BENEFICIAL EFFECTS OF COTININE ON COGNITION
Thus far, the molecular mechanisms of cotinine action have been
elusive. A previous report suggested that cotinine binds to an
unknown type of receptor (Riah et al., 2000). Unfortunately, no
follow-up studies pursued the characterization of this “cotinine
receptor”. Other study based in the fact that cotinine increased
serotonin levels in the rat brain, investigated whether granisetron,
a 5HT(3) receptor antagonist, could enhance the efficacy of the
nicotine patch. The results indicated that 5HT(3) antagonism was
an unlikely mechanism of cotinine’s actions (Hatsukami et al.,
2003). On the other hand, pharmacological evidence using 125I-
labeledα-bungarotoxin and [3H] nicotine to differentiate subtypes
of nAChRs affinities show that cotinine is a weak agonist of the α7
nAChRs and nicotine has more than 100 times higher affinity than
cotinine for agonist binding sites of both subtypes of receptors.
In addition the toxicological analysis using acute intraperitoneal
injections of drugs in saline, showed that cotinine has in com-
parison to nicotine less than 1.5% toxicity (Table 1; Riah et al.,
1999).
It has been suggested that α7 nAChRs is not the main tar-
get of cotinine (Riah et al., 1999) and other type of receptors
for cotinine have been suggested (Riah et al., 2000). Also, using
[3H]dopamine release assays and ligand-binding autoradiography
in monkey striatum, it was concluded that cotinine function-
ally interacts with both α4β2 and α3α6β2 nAChR subtypes in
the caudate with a IC50 for the inhibition of specific agonists in
the micromolar range (O’Leary et al., 2008). In recent years, we
and others have proposed that cotinine functions as a positive
allosteric modulator of α7 nAChRs (Buccafusco et al., 2009; Zeitlin
et al., 2012). Positive allosteric modulators, are compounds that
facilitate endogenous neurotransmission without directly stimu-
lating the target receptors (Bertrand and Gopalakrishnan, 2007;
Faghih et al., 2007). For example the compound PNU-120596,
acts as a positive allosteric modulator of nAChRs both in vitro
and in vivo (see Young et al., 2008). PNU-120596 inhibited the
ability of amphetamine to suppress auditory gating in rats, sug-
gesting its potential for use in schizophrenia, characterized by
auditory gating deficits. The effects of PNU-120596 in vitro were
shown to be mediated by α7 nAChRs. As a positive allosteric mod-
ulator, PNU-120596 positively modulates nicotinic cholinergic
neurotransmission mostly by preventing receptor desensitization.
Because, cotinine has been shown to be a memory enhancer
(Echeverria et al., 2011), and also inhibit sensory gating disrup-
tion it has been speculated that can have similar beneficial effects
on memory in AD or schizophrenia (Hajos and Rogers, 2010).
However this is highly speculative at this point and needs to be
demonstrated.
Another hypothesis proposed to explain the beneficial effects
of cotinine on cognition is the theory of desensitization of spe-
cific population of the α7nAChRs. This hypothesis speculates that
cotinine desensitization of the α7 nAChRs expressed on inhibitory
GABAergic neurons of the hippocampus, may result in the acti-
vation of excitatory glutamate receptors mediating the synaptic
plasticity changes required for memory (Buccafusco et al., 2007,
2009). Functional assays of human α7 nAChR expressed in Xeno-
pus leavis oocytes showed that cotinine acted as weak agonists at
the human α7 nAChR (1% response at 1 mM) and inhibited the
response to ACh with IC50 value of 175µM (Briggs and McKenna,
1998). Although this hypothesis is intriguing, the doses required
for inducing the receptor desensitization are higher than those
showing pharmacological effects and direct evidence that cotinine
may have this effect in the brain is still missing. The idea of a
desensitization of the α7nAChR induced by cotinine is contradic-
tory with the fact that in mice, the chronic treatment with cotinine
induced the activation of the Akt/GSK3β signaling pathway, which
is activated by the α7 nAChR, in both the hippocampus and cortex
(Echeverria et al., 2011). In fact, cotinine prevented apomorphine-
induced deficits in PPI of acoustic startle in rats (Buccafusco and
Terry, 2003), a behavioral task that greatly depends on the activity
of the α7 nAChR. The effects of cotinine can be better explained
by cotinine functioning as a positive allosteric modulator of the
human α7 nAChR.
As a positive modulator, cotinine may improve learning and
memory performance and reverse the apomorphine-induced
deficits of PPI, in addition to stimulating the protein kinase B
(Akt)/GSK3β pathway. Furthermore, stimulation of α7 nAChR
signaling may explain the neuroprotective effects of cotinine
because Akt can promote neuronal survival via several mecha-
nisms including stimulation of the expression of anti-apoptotic
factors such as CREB and Bcl-2 while inactivating pro-apoptotic
enzyme such as Ask1 (Kim et al., 2001). Evidence of an allosteric
effect of cotinine on the α7 nAChR or other receptors.
CONCLUSION
Altogether the evidence suggests that cotinine is less toxic and
has different mechanism(s) of action than nicotine. Cotinine’s
properties and the preclinical evidence of its nootropic effects in
animal models of psychiatric conditions, suggests that cotinine as
a pure agent, in absence of nicotine, represents a new therapeutic
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agent to reduce anxiety, facilitate the extinction of fear memories,
and improve attention and working memory in individuals with
psychiatric conditions such as AD.
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